© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 20, 1708-1710,
October 20, 1999
© 1999 Oxford University Press
NEWS |
Scientific Interest in Newcastle Disease Virus Is Reviving
The story of Newcastle disease virus therapy has taken many twists and turns — spanning two continents and many decades.
Early success with the viral vaccine in humans was first reported in the United States in the early 1980s, but it is not until recently that interest in the virus has resurfaced both in the alternative medicine community and among researchers in academia and private industry. The National Cancer Institute has just signed a Cooperative Research and Development Agreement with Pro-Virus, Inc., in Gaithersburg, Md., to carry out early trials, and phase III trials are beginning in Europe.
Several scientists now agree that Newcastle disease therapy has all the hallmarks of
"promise." The virus preferentially kills tumor cell lines, is remarkably effective in
killing tumors in animals, and appears to be both safe and to varying degrees, effective in phase II
studies both here and in Europe. Moreover, the therapy
Newcastle Pioneer
European Trials
Hungarian Link
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Krishnamurthy, T. Takimoto, R. A. Scroggs, and A. Portner Differentially regulated interferon response determines the outcome of newcastle disease virus infection in normal and tumor cell lines. J. Virol., June 1, 2006; 80(11): 5145 - 5155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Karcher, G. Dyckhoff, P. Beckhove, C. Reisser, M. Brysch, Y. Ziouta, B. H. Helmke, H. Weidauer, V. Schirrmacher, and C. Herold-Mende Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells Cancer Res., November 1, 2004; 64(21): 8057 - 8061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Steiner, M. M. Bonsanto, P. Beckhove, M. Brysch, K. Geletneky, R. Ahmadi, R. Schuele-Freyer, P. Kremer, G. Ranaie, D. Matejic, et al. Antitumor Vaccination of Patients With Glioblastoma Multiforme: A Pilot Study to Assess Feasibility, Safety, and Clinical Benefit J. Clin. Oncol., November 1, 2004; 22(21): 4272 - 4281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakaya, T. Nakaya, M.-S. Park, J. Cros, J. Imanishi, P. Palese, and A. Garcia-Sastre Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors J. Virol., September 1, 2004; 78(17): 9366 - 9375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Washburn, M. A. Weigand, A. Grosse-Wilde, M. Janke, H. Stahl, E. Rieser, M. R. Sprick, V. Schirrmacher, and H. Walczak TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus J. Immunol., February 15, 2003; 170(4): 1814 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Pecora, N. Rizvi, G. I. Cohen, N. J. Meropol, D. Sterman, J. L. Marshall, S. Goldberg, P. Gross, J. D. O'Neil, W. S. Groene, et al. Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers J. Clin. Oncol., May 1, 2002; 20(9): 2251 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakaya, J. Cros, M.-S. Park, Y. Nakaya, H. Zheng, A. Sagrera, E. Villar, A. Garcia-Sastre, and P. Palese Recombinant Newcastle Disease Virus as a Vaccine Vector J. Virol., December 1, 2001; 75(23): 11868 - 11873. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. K. Csatary, E. Csatary, and R. W. Moss Re: Scientific Interest in Newcastle Disease Virus Is Reviving J Natl Cancer Inst, March 15, 2000; 92(6): 493 - 493. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Nelson RESPONSE: Re: Scientific Interest in Newcastle Disease Virus Is Reviving J Natl Cancer Inst, March 15, 2000; 92(6): 493a - 494a. [Full Text] [PDF]
|
|